Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will participate in a panel discussion titled Miss Con-GENE-iality - Updates in Gene Tx at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 12:00 PM ET. The event will be accessible via live and archived webcasts on the company’s website for 90 days. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, with a commitment to efficient drug development and addressing unmet medical needs.

NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President will participate in a panel titled Miss Con-GENE-iality - Updates in Gene Tx on Wednesday, August 11, 2021 at the Wedbush PacGrow Healthcare Conference at 12:00 PM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370

FAQ

What is the date and time of the Ultragenyx panel at the Wedbush PacGrow Healthcare Conference?

The Ultragenyx panel is scheduled for August 11, 2021, at 12:00 PM ET.

Who is presenting at the Ultragenyx panel discussion?

Emil D. Kakkis, M.D., Ph.D., the CEO of Ultragenyx, will be presenting.

How can I access the Ultragenyx panel discussion webcast?

The live and archived webcast can be accessed on Ultragenyx's website for 90 days after the event.

What topics will be covered in the Ultragenyx panel discussion?

The panel discussion will focus on updates in gene therapy, titled Miss Con-GENE-iality - Updates in Gene Tx.

What is Ultragenyx Pharmaceutical's primary focus?

Ultragenyx is focused on developing novel therapies for serious rare and ultra-rare genetic diseases.